Draupnir Bio Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 15


  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $9M

  • Investors
  • 5

Draupnir Bio General Information


Developer of cholesterol-lowering medicine designed to prevent blood clots in the heart more effectively than the current medicine. The company's platform technology enables the development of protein degraders that target extracellular disease proteins, with the potential to target the human proteome and offer broad disease applicability across multiple areas of unmet therapeutic need

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Corporate Office
  • Ole Maaloes Vej 3
  • 2200 Copenhagen
  • Denmark
+45 51 00 00 00

Draupnir Bio Timeline

Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Draupnir Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Early Stage VC 31-Dec-2021 $9M 000.00 000.00 Completed Pre-Clinical Trials
6. Early Stage VC 31-Dec-2020 00.000 000.00 000.00 Completed Pre-Clinical Trials
5. Early Stage VC (Series A) 01-Oct-2019 000.00 000.00 Completed Pre-Clinical Trials
4. Angel (individual) 31-Dec-2018 000.00 000.00 0000 Completed Pre-Clinical Trials
3. Grant 30-Nov-2017 00.000 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Jan-2017 Completed Pre-Clinical Trials
1. Spin-Off 01-Jan-2017 Completed Pre-Clinical Trials
To view Draupnir Bio’s complete valuation and funding history, request access »

Draupnir Bio Executive Team (8)

Name Title Board Seat Contact Info
Andrew Hotchkiss Chief Executive Officer
Simon Feldbæk Chief Technology Officer & Head of Research & Development
Simon Glerup Ph.D Co-Founder, Chief Scientific Officer & Board Member
Casper Hansen Chief Business Officer
Camilla Gustafen Ph.D Co-Founder & Vice President of Biology
You’re viewing 5 of 8 executive team members. Get the full list »

Draupnir Bio Board Members (7)

Name Representing Role Since
Emmanuelle Coutanceau Ph.D Novo Holdings Board Member 000 0000
Eva-Lotta Allan Self Chairman 000 0000
Ivan Burkov Ph.D Inkef Board Member 000 0000
Robert Scott MD Self Board Member 000 0000
Roel Bulthuis Inkef Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Draupnir Bio Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Draupnir Bio Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Gilde Healthcare Venture Capital Minority 000 0000 000000 0
High-Tech Gründerfonds Venture Capital Minority 000 0000 000000 0
Inkef Venture Capital Minority 000 0000 000000 0
Novo Holdings Asset Manager Minority 000 0000 000000 0
Accelerace Accelerator/Incubator 000 0000 000000 0
To view Draupnir Bio’s complete investors history, request access »

Draupnir Bio FAQs

  • When was Draupnir Bio founded?

    Draupnir Bio was founded in 2017.

  • Who is the founder of Draupnir Bio?

    Simon Glerup Ph.D, Camilla Gustafen Ph.D, and Peder Madsen are the founders of Draupnir Bio.

  • Who is the CEO of Draupnir Bio?

    Andrew Hotchkiss is the CEO of Draupnir Bio.

  • Where is Draupnir Bio headquartered?

    Draupnir Bio is headquartered in Copenhagen, Denmark.

  • What is the size of Draupnir Bio?

    Draupnir Bio has 15 total employees.

  • What industry is Draupnir Bio in?

    Draupnir Bio’s primary industry is Drug Discovery.

  • Is Draupnir Bio a private or public company?

    Draupnir Bio is a Private company.

  • What is the current valuation of Draupnir Bio?

    The current valuation of Draupnir Bio is 000.00.

  • What is Draupnir Bio’s current revenue?

    The current revenue for Draupnir Bio is 000000.

  • How much funding has Draupnir Bio raised over time?

    Draupnir Bio has raised $50.9M.

  • Who are Draupnir Bio’s investors?

    Gilde Healthcare, High-Tech Gründerfonds, Inkef, Novo Holdings, and Accelerace have invested in Draupnir Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »